European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Adverio Pharma GmbH, Leverkusen, Germany

Watch
Adverio Pharma GmbH

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Premium Service
Unlock Dossier
What is a Dossier?
A dossier provides comprehensive company details as a PDF, together with all underlying original publications and original data in one place.
The download feature is exclusively available for our paid plan. Upgrade your account to access:
Quick Dossier
Entire company details as a PDF
Power Dossier
Entire company details along with all original publications / original data bundled in a ZIP file
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more
Learn more
View plans

Name

Adverio Pharma GmbH

Identification

Ut
District Court of Cologne HRB 103180
Ut
District Court of Cottbus HRB 11692
Lei
549300U3IC9UCOLHS234
EUID
DER3306.HRB103180

Address

Kaiser-Wilhelm-Allee 1, 51373 Leverkusen, Germany
Schönefeld, Germany

Corporate purpose

The preservation and administration of intellectual property, in particular industrial property rights such as patents, trademarks, utility models, designs and know-how as well as their commercial exploitation within the framework of existing or to be concluded cooperations with third parties worldwide in the pharmaceutical industry.

History

Persons

Marketing & Tech

Network

Loading network

Legal Structure

Current legal representatives Legal form information · Proxy policies Premium
Premium
1Managing Director
2Authorized signatory (ppa)
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans
tax haven banner
Ownership relations Premium + Ownership & Flags add-on
Premium + Ownership & Flags add-on
Shareholders and Investors
2 known active shareholders
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Publications

12 Mar 2025
Patent: Nanoformulations of methyl{4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridine-3-YL]pyrimidine-5-YL}Carbamate
21 Oct 2024
Control: Bayer Pharma AG · No longer Control: Bayer Intellectual Property GmbH
21 Oct 2024
As not registered, it is published: To the creditors of the Company whose claims have been substantiated ...
24 Sept 2024
Original document: “Unternehmensvertrag / Umwandlungsvertrag / sonstiger Vertrag“
1 Jul 2024
Original document: “Liste der Gesellschafter“
19 May 2022 via Bayer AG also 07/08/2020, 22/05/2019, 25/04/2018, 16/04/2018, 17/05/2017, 22/04/2016, 21/04/2015
Shareholder: Bayer AG
11 Apr 2022
Managing Director: Markus Albers · No longer Managing Director: Andreas Nauck
18 Jan 2022
Original document: “Liste der Gesellschafter“
13 Jan 2022
Original document: “Liste der Gesellschafter“
28 Dec 2021
No longer Authorized signatory (ppa) (1)
10 Nov 2021
Authorized signatory (ppa): Gregor Ch. Schwartze
15 Jun 2021
Patent: Process for Preparing Methyl {4,6-Diamino-2-[5-Fluoro-1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridin-3-YL]Pyrimidin-5-YL}Carbamate
20 Jan 2021
Patent: Substituted 5-fluoro-1H-pyrazolopyridines in crystalline form
12 Nov 2020
No longer Authorized signatory (ppa): Thomas Bögner
13 Oct 2020
Change of headquarters: Adverio Pharma GmbH · Seat: Leverkusen
30 Sept 2020
MD: A. N. · ppa (3) · Control: Bayer Intellectual Property GmbH · Change of headquarters: Adverio Pharma GmbH · Address · Capital: €25,000 · Share­holder agreement · Proxy policy · Corporate Purpose
14 Sept 2020
Original document: “Liste der Gesellschafter“
14 Sept 2020
Original document: “Liste der Gesellschafter“
14 Sept 2020
Original document: “Liste der Gesellschafter“
14 Sept 2020
Original document: “Liste der Gesellschafter“
4 Sept 2020
Original document: “Gesellschaftsvertrag / Satzung / Statut“
15 Jul 2020
Patent: Forms of Methyl {4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridino-3-YL]Pyrimidino-5-YL}Methyl Carbamate
16 Jun 2020
Patent: Process for Preparing Methyl {4,6-Diamino-2-[5-Fluoro-1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridin-3-YL]Pyrimidin-5-YL}Carbamate
6 May 2020
Authorized signatory (ppa): Thomas Bögner · No longer Managing Director: Thomas Bögner
29 Feb 2020
Address
15 Jan 2020
Patent: Process for the preparation of 4-(2,2,3,3-tetrafluoropropyl)morpholine
25 Dec 2019
Patent: Method for the Preparation of Methyl-{4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridin-3-YL]Pyrimidin-5-YL}Methylcarbamate
16 Dec 2019
Patent: Methyl {4,6-Diamino-2-[5-Fluoro-1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridin-3-YL]Pyrimidin-5-YL}Carbamate Active Compound Product Having Improved Properties, Production and Formulation …
4 Jun 2019
Share­holder agreement
28 May 2019
Patent: Method of Identifying a Subgroup of Patients Suffering From Dcssc Which Benefits From a Treatment with SGC Stimulators and SGC Activators in a Higher Degree Than a Control Group
29 Mar 2019
Original document: “Gesellschaftsvertrag / Satzung / Statut“
4 Dec 2018
Managing Director: Andreas Nauck · No longer Managing Director: Franz Kunisch
1 Aug 2018
Patent: Method for Producing Substituted 5-Fluoro-1H-Pyrazolopyridines
1 Aug 2018
Patent: Process for the production of methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidine-5-yl}methylcarbamate for use as an active pharmaceutical ingredient
11 Jun 2018
Patent: SGC Stimulators and SGC Activators for USE in Preventing or Delaying Disease Progression or Stabilizing Disease in Patients Suffering From Diffuse Cutaneous Systemic Sclerosis (Dcssc)
20 Dec 2017
Managing Director: Thomas Bögner · No longer Managing Director: Detlev Hessenbruch
5 Oct 2016
Patent: Method for Producing Substituted (Z)-Alpha-Fluoro-Beta-Amino-Acrylaldehydes
27 Jan 2016
Patent: Substituted 5-Fluoro-1H-Pyrazolopyridines and USE Thereof
7 Oct 2015
Patent: Process for the preparation of methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidine-5-yl}-methylcarbamate and its purification for use as an active …
12 Aug 2015
Patent: SGC stimulators or SGC activators Alone and in combination with PDE5 inhibitors for the treatment of cystic fibrosis
24 Jun 2015
Patent: The USE of sGC Stimulators, sGC Activators, Alone and Combinations with PDE5 Inhibitors for the Treatment of Systemic Sclerosis (SSc)
24 Dec 2014
Managing Director: Franz Kunisch
11 Nov 2014
Authorized signatory (ppa) (2) · Control: Bayer Intellectual Property GmbH
1 Oct 2014
Patent: Process for the Purification of Methyl-{4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridin-3-YL]Pyrimidin-5-YL}Methylcarbamate
28 Aug 2014
Patent: Formen von {4,6-Diamino-2-[1-(2-Fluorbenzyl)-1H-Pyrazolo[3,4-B]Pyridino-3-YL]Pyrimidino-5-YL}Methylcarbamat
28 Aug 2014
Patent: Formen von {4,6-Diamino-2-[1-(2-Fluorbenzyl)-1H-Pyrazolo[3,4-B]Pyridino-3-YL]Pyrimidino-5-YL}Methylcarbamat
28 Aug 2014
Patent: Formen von {4,6-Diamino-2-[1-(2-Fluorbenzyl)-1H-Pyrazolo[3,4-B]Pyridino-3-YL]Pyrimidino-5-YL}Methylcarbamat
15 Aug 2014
Reg­is­tra­tion · Managing Director: Detlev Hessenbruch · Capital: €25,000 · Share­holder agreement · Legal form: GmbH · Proxy policy · Corporate Purpose
15 Jul 2014
Original document: “Liste der Gesellschafter“
15 Jul 2014
Original document: “Liste der Gesellschafter“
8 Jul 2014
Original document: “Gesellschaftsvertrag / Satzung / Statut“
25 Jun 2014
Patent: Sgc Stimulators and Activators in Combination with pde5 Inhbitors for the Treatment of Erectile Dysfunction
21 May 2014
Patent: Process for the preparation of methyl--4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidine-5-yl-methylcarbalate for use as a pharmaceutical active ingredient
18 Feb 2014
Patent: Forms of Methyl {4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridino-3-YL]Pyrimidino-5-YL}Methyl Carbamate
There are no publications matching your search.

Mentions

2 Feb 2026 in Ler
Direct parent
2 Feb 2026 in Ler
Ultimate parent
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.